Format

Send to

Choose Destination
Nutr Neurosci. 2018 Apr;21(3):224-228. doi: 10.1080/1028415X.2017.1283128. Epub 2017 Feb 22.

Adjunctive low-dose docosahexaenoic acid (DHA) for major depression: An open-label pilot trial.

Author information

1
a Faculty of Medicine, Department of Psychiatry , The University of Melbourne , Australia.
2
b Centre for Human Psychopharmacology , Swinburne University of Technology , Australia.

Abstract

OVERVIEW:

Whilst the majority of evidence supports the adjunctive use of eicosapentaenoic acid (EPA) in improving mood, to date no study exists using low-dose docosahexaenoic acid (DHA) alone as an adjunctive treatment in patients with mild to moderate major depressive disorder (MDD).

METHODS:

A naturalistic 8-week open-label pilot trial of low-dose DHA, (260 mg or 520 mg/day) in 28 patients with MDD who were non-responsive to medication or psychotherapy, with a Hamilton Depression Rating Scale (HAM-D) score of greater than 17, was conducted. Primary outcomes of depression, clinical severity, and daytime sleepiness were measured.

RESULTS:

After 8 weeks, 54% of patients had a ≥50% reduction on the HAM-D, and 45% were in remission (HAM-D ≤ 7). The eta-squared statistic (0.59) indicated a large effect size for the reduction of depression (equivalent to Cohen's d of 2.4). However confidence in this effect size is tempered due to the lack of a placebo. The mean score for the Clinical Global Impression Severity Scale was significantly improved by 1.28 points (P < 0.05). Despite a significant reduction in the HAM-D score for middle insomnia (P = 0.02), the reduction in excessive daytime somnolence on the total Epworth Sleepiness Scale (ESS) did not reach significance. No significant adverse reactions to DHA were found.

CONCLUSION:

Within the major limits of this open-label pilot study, the results suggest that DHA may provide additional adjunctive benefits in patients with mild- to -moderate depression.

KEYWORDS:

Adjunctive; DHA; Depression; Docosahexaenoic acid; Omega-3

PMID:
28224818
DOI:
10.1080/1028415X.2017.1283128
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center